Inhibitors of fatty acid binding proteins (FABPS), methods of use and methods of making

Substituted 2-amino-pyridinyl compounds inhibit FABP3, FABP4, and FABP5 to treat TNBC, HCC, autoimmune diseases, and metabolic disorders by modulating immune cell metabolism, offering improved therapeutic options for these conditions.

WO2025226670A1 Publication Date: 2025-10-30CELLORAM INC
12 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/025755
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-07-10
Filing Date
2025-04-22
Publication Date
2025-10-30

AI Technical Summary

Technical Problem

Current treatments for conditions associated with fatty acid binding proteins (FABPs), such as triple-negative breast cancer (TNBC), Hepatocellular carcinoma (HCC), autoimmune diseases, viral infections, and metabolic disorders like obesity and atherosclerosis, lack effective targeted therapies, and existing FABP inhibitors are not sufficiently improved.

Method used

Development of substituted 2-amino-pyridinyl compounds that act as inhibitors of FABP3, FABP4, FABP5, and FABP7, modulating immune cell metabolism and function to treat conditions like cancer, autoimmune diseases, and metabolic disorders by administering these compounds in pharmaceutical compositions.

Benefits of technology

The compounds effectively inhibit FABP activity, enhancing anti-tumor responses, improving immune cell function, and treating a range of diseases including cancer, autoimmune disorders, and metabolic disorders by modulating lipid metabolism and immune cell regulation.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed herein are FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases including cancers that highly express any of these FABPs, in particular triple-negative breast cancer (TNBC), hepatocellular carcinoma and other inflammation-induced diseases including cardiovascular disease, obesity or an obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting glucose, vitiligo, psoriasis, viral infection, pain and dementia. Also disclosed herein are methods for preparing the disclosed compounds.
Need to check novelty before this filing date? Find Prior Art